Market research
ISR IsoRay, Inc
NYSE MKT USD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 107M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 1.49
Profile
Instrument facts
- Exchange
- NYSE MKT
- Currency
- USD
- Sector
- Healthcare
- Industry
- Healthcare Equipment & Supplies
- ISIN
- Not available
- Market cap
- 107M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 1.49
About
About IsoRay, Inc
Isoray, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Research context
IsoRay, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Healthcare Equipment & Supplies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ISR discussion.
5 years, 7 months ago
Isoray, Inc is currently in a long term downtrend where the price is trading 18.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.0.
Isoray, Inc's total revenue rose by 6.9% to $2M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-868 since the same quarter in the previous year.
Finally, its free cash flow grew by 8.2% to $-1M since the same quarter in the previous year.
Based on the above factors, Isoray, Inc gets an overall score of 4/5.